Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ）
Status:
Recruiting
Trial end date:
2024-03-29
Target enrollment:
Participant gender:
Summary
The trial is prospective, randomized, open-label, blinded endpoint (PROBE) design. Patients
with acute ischemic stroke, who are eligible for standard intravenous thrombolysis within 4.5
hours of stroke onset will be randomized 1:1 to 0.25mg/kg or 0.9 mg/kg alteplase before all
participants undergo endovascular thrombectomy.
Phase:
Phase 3
Details
Lead Sponsor:
Beijing Tiantan Hospital
Collaborators:
Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd The Place Pharmaceutical(Jiangsu) Co., Ltd